Cognate BioServices has completed a management buyout (“MBO”) and raised capital from a group of global investment firms including Santa Monica, Calif.-based Tennenbaum Capital Partners (“TCP”), Medivate Partners, and affiliates based in Seoul, South Korea.   “As an early investor in Cognate, we are very excited to expand our partnership with the company,” said Dan Worrell, managing director of TCP. “For the past two decades, TCP’s healthcare strategy has focused on investing in companie...